1.83

3.39% 0.06

After Hours: 2.00 0.17 +9.29%

Pyxis Oncology Inc (PYXS)

Overview News Price History Option Chain Financials Why PYXS Down? Discussions Forecast

Pyxis Oncology Inc stock is traded at $1.83, with a volume of 1.83M. It is up +3.39% in the last 24 hours and down -50.00% over the past month. Pyxis Oncology Inc is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. It develops the product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion.

Previous Close:

$1.77

Open:

$1.77

24h Volume:

1.83M

Relative Volume:

1.92

Market Cap:

$105.25M

Revenue:

Net Income/Loss:

$-73.79M

P/E Ratio:

-0.6444

EPS:

-2.84

Net Cash Flow:

$-77.44M

1W Performance:

-52.09%

1M Performance:

-50.00%

6M Performance:

-51.97%

1Y Performance:

+18.06%

1-Day Range:

$1.76

$1.875

1-Week Range:

$1.76

$2.39

52-Week Range:

$1.48

$6.85

Pyxis Oncology Inc Stock (PYXS) Company Profile

Name

Pyxis Oncology Inc

Sector

Healthcare (1200)

Industry

Biotechnology (682)

Phone

(617) 221-9059

Address

321 HARRISON AVENUE, BOSTON

Employee

Twitter

Next Earnings Date

2024-08-11

Latest SEC Filings

PYXS's Discussions on Twitter

Compare PYXS with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
PYXS Pyxis Oncology Inc	1.83	105.25M	0	-73.79M	-77.44M	-2.84
VRTX Vertex Pharmaceuticals Inc	464.56	119.70B	10.63B	-479.80M	-1.35B	13.33
REGN Regeneron Pharmaceuticals Inc	754.87	82.75B	13.85B	4.65B	3.32B	35.06
ARGX Argen X Se Adr	614.59	36.73B	1.86B	-40.29M	-1.28B	-4.16
ALNY Alnylam Pharmaceuticals Inc	253.74	32.53B	2.09B	-332.26M	16.06M	-4.14
BNTX Biontech Se Adr	120.72	28.50B	3.30B	-501.07M	1.03B	11.54

Pyxis Oncology Inc Stock (PYXS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-21-24	Downgrade	William Blair	Outperform → Mkt Perform
Nov-08-24	Initiated	Stephens	Overweight
Aug-08-24	Initiated	Stifel	Buy
May-07-24	Resumed	Jefferies	Buy
Feb-09-24	Initiated	BTIG Research	Buy
Jan-23-24	Initiated	Leerink Partners	Outperform
Sep-05-23	Initiated	RBC Capital Mkts	Outperform
Nov-02-21	Initiated	BofA Securities	Neutral
Nov-02-21	Initiated	Credit Suisse	Outperform
Nov-02-21	Initiated	Jefferies	Buy

View All

Pyxis Oncology Inc Stock (PYXS) Latest News

Nov 27, 2024

Pyxis Oncology CFO acquires shares worth $174,364 - Investing.com

Nov 27, 2024

Institutional owners may ignore Pyxis Oncology, Inc.'s (NASDAQ:PYXS) recent US$142m market cap decline as longer-term profits stay in the green - Yahoo Finance

Nov 27, 2024

Nov 26, 2024

Pressure on Pyxis despite promising PYX-201 data - The Pharma Letter

Nov 26, 2024

Nov 25, 2024

Pyxis Oncology's SWOT analysis: ADC innovator's stock poised for growth By Investing.com - Investing.com UK

Nov 25, 2024

Pyxis Oncology (NASDAQ:PYXS) Downgraded by William Blair to “Market Perform” - Defense World

Nov 25, 2024

Royal Bank of Canada Boosts Pyxis Oncology (NASDAQ:PYXS) Price Target to $10.00 - Defense World

Nov 25, 2024

Stock market news: Perspective Therapeutics -44.33%, Pyxis Oncology -42.93% among top losers during mid day trading - Business Upturn

Nov 21, 2024

Pyxis stock craters 46% amid Phase 1 data, William Blair downgrade (NASDAQ:PYXS) - Seeking Alpha

Nov 21, 2024

Stock market today: Pyxis Oncology plunges by 47.25% while Perspective Therapeutics declines by 46.68% in early trading - Business Upturn

Nov 21, 2024

Stock market today: SCWorx Corp. gains 141.81% while Pyxis Oncology down by 46.41% in early trading - Business Upturn

Nov 21, 2024

Pyxis Oncology's Cancer Drug Progress Stirs Analyst Concerns - Benzinga

Nov 21, 2024

Pyxis Oncology (NASDAQ:PYXS) Rating Lowered to Market Perform at William Blair - MarketBeat

Nov 21, 2024

Pyxis Oncology (NASDAQ:PYXS) Earns Buy Rating from HC Wainwright - MarketBeat

Nov 21, 2024

PYXS shares target upgraded, outperform on positive trial data - Investing.com

Nov 21, 2024

Institutional investors in Pyxis Oncology, Inc. (NASDAQ:PYXS) lost 11% last week but have reaped the benefits of longer-term growth - Simply Wall St

Nov 21, 2024

Nov 20, 2024

Pyxis Oncology plummets 38% on preliminary phase 1 data for cancer asset - Seeking Alpha

Nov 20, 2024

Pyxis Oncology Reports Promising Phase 1 Trial Results - TipRanks

Nov 20, 2024

Pyxis Oncology announces preliminary PYX-201 data, collaboration with Merck - TipRanks

Nov 20, 2024

Pyxis Oncology Announces Favorable Preliminary PYX-201 Clinical Phase 1 Part 1 Data - The Manila Times

Nov 20, 2024

Pyxis Oncology, Inc. Announces Favorable Preliminary PYX-201 Clinical Phase 1 Part 1 Data - Marketscreener.com

Nov 20, 2024

Nov 18, 2024

EPOCH 47: BIOTECH MARKET RESEARCH $PYXS - substack.com

Nov 18, 2024

Pyxis Oncology, Inc. (NASDAQ:PYXS) Receives $9.57 Consensus Target Price from Analysts - MarketBeat

Nov 18, 2024

Nov 17, 2024

Pyxis Oncology, Inc. (NASDAQ:PYXS) Short Interest Up 19.3% in October - MarketBeat

Nov 17, 2024

Nov 15, 2024

Pyxis Oncology FY2024 EPS Forecast Lowered by HC Wainwright - MarketBeat

Nov 15, 2024

FY2024 EPS Estimates for Pyxis Oncology Reduced by Analyst - MarketBeat

Nov 15, 2024

Nov 14, 2024